The daily practice of pancreatic enzyme replacement therapy after pancreatic surgery: a northern European survey: enzyme replacement after surgery
- PMID: 22711213
- PMCID: PMC3399077
- DOI: 10.1007/s11605-012-1927-1
The daily practice of pancreatic enzyme replacement therapy after pancreatic surgery: a northern European survey: enzyme replacement after surgery
Abstract
Introduction: After pancreatic surgery, up to 80 % of patients will develop exocrine insufficiency. For enzyme supplementation to be effective, prescribing an adequate dose of pancreatic enzymes is mandatory but challenging because the required dose varies. Data on the practice of enzyme replacement therapy after surgery are lacking, and therefore, we conducted this analysis.
Methods: An anonymous survey was distributed to members of the Dutch and German patient associations for pancreatic disorders. The target population consisted of patients with chronic pancreatitis or pancreatic cancer who had undergone pancreatic surgery and were using enzymes to treat exocrine insufficiency. Results were compared to a similar group of non-operated patients.
Results: Ninety-one cases were analyzed (84 % underwent a resection procedure). The median daily enzyme dose was 6, and 25 % took three or less capsules. Despite treatment, 68 % of patients reported steatorrhea-related symptoms, 48 % adhered to a non-indicated dietary fat restriction, and only 33 % had visited a dietician. The outcome was equally poor for the 91 non-operated patients.
Conclusion: Most patients suffering from exocrine insufficiency after pancreatic surgery are undertreated. To improve efficacy, physicians should be more focused on treating exocrine insufficiency and educate patients to adjust the dose according to symptoms and their diet.
Similar articles
-
Patients with exocrine insufficiency due to chronic pancreatitis are undertreated: a Dutch national survey.Pancreatology. 2012 Jan-Feb;12(1):71-3. doi: 10.1016/j.pan.2011.12.010. Epub 2011 Dec 31. Pancreatology. 2012. PMID: 22487479
-
COMPARING THE ENZYME REPLACEMENT THERAPY COST IN POST PANCREATECTOMY PATIENTS DUE TO PANCREATIC TUMOR AND CHRONIC PANCREATITIS.Arq Gastroenterol. 2016 Apr-Jun;53(2):94-7. doi: 10.1590/S0004-28032016000200008. Arq Gastroenterol. 2016. PMID: 27305415
-
Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis.Eur J Gastroenterol Hepatol. 1996 Jul;8(7):699-703. Eur J Gastroenterol Hepatol. 1996. PMID: 8853261 Clinical Trial.
-
Pancreatic exocrine insufficiency following pancreatic resection.Pancreatology. 2015 Sep-Oct;15(5):449-455. doi: 10.1016/j.pan.2015.06.003. Epub 2015 Jun 23. Pancreatology. 2015. PMID: 26145836 Review.
-
Enzyme treatment after gastrointestinal surgery.Digestion. 1993;54 Suppl 2:48-53. doi: 10.1159/000201104. Digestion. 1993. PMID: 8224572 Review.
Cited by
-
Application of an early oral feeding protocol after pylorus-preserving pancreaticoduodenectomy.Support Care Cancer. 2019 Mar;27(3):981-990. doi: 10.1007/s00520-018-4387-7. Epub 2018 Aug 15. Support Care Cancer. 2019. PMID: 30112720
-
Update on the diagnosis and management of exocrine pancreatic insufficiency.F1000Res. 2019 Nov 26;8:F1000 Faculty Rev-1991. doi: 10.12688/f1000research.20779.1. eCollection 2019. F1000Res. 2019. PMID: 31824646 Free PMC article. Review.
-
Nanofibrous Formulation of Cyclodextrin Stabilized Lipases for Efficient Pancreatin Replacement Therapies.Pharmaceutics. 2021 Jun 27;13(7):972. doi: 10.3390/pharmaceutics13070972. Pharmaceutics. 2021. PMID: 34199011 Free PMC article.
-
A National Audit of Pancreatic Enzyme Prescribing in Pancreatic Cancer from 2015 to 2023 in England Using OpenSAFELY-TPP.Semin Oncol Nurs. 2023 Jun;39(3):151439. doi: 10.1016/j.soncn.2023.151439. Epub 2023 May 2. Semin Oncol Nurs. 2023. PMID: 37142468 Free PMC article.
-
Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension.Aliment Pharmacol Ther. 2013 Apr;37(7):691-702. doi: 10.1111/apt.12236. Epub 2013 Feb 5. Aliment Pharmacol Ther. 2013. PMID: 23383603 Free PMC article. Clinical Trial.
References
-
- Layer P, Go VL, DiMagno EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol. 1986;251:G475–G480. - PubMed
-
- Bruno MJ. Maldigestion and exocrine pancreatic insufficiency after pancreatic resection for malignant disease: pathophysiology and treatment. Pancreatology. 2001;1:55–61. doi: 10.1159/000055893. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical